Daily Sepsis Research Analysis
Three impactful sepsis studies emerged: a Nature Communications paper presents a six-gene, point-of-care microfluidic assay that predicts 24-hour deterioration; a mechanistic study in Journal of Neuroinflammation identifies endothelial TREM-1 as a driver of blood–brain barrier disruption and cognitive impairment via PI3K/Akt; and a prospective ED cohort shows MR-proADM outperforms common biomarkers and scores for predicting septic shock/ICU admission and 30-day mortality.
Summary
Three impactful sepsis studies emerged: a Nature Communications paper presents a six-gene, point-of-care microfluidic assay that predicts 24-hour deterioration; a mechanistic study in Journal of Neuroinflammation identifies endothelial TREM-1 as a driver of blood–brain barrier disruption and cognitive impairment via PI3K/Akt; and a prospective ED cohort shows MR-proADM outperforms common biomarkers and scores for predicting septic shock/ICU admission and 30-day mortality.
Research Themes
- Point-of-care genomic diagnostics for early sepsis deterioration
- Endothelial mechanisms and neuroinflammation in sepsis-associated encephalopathy
- Risk stratification and prognostic biomarkers in emergency department sepsis
Selected Articles
1. A machine learning and centrifugal microfluidics platform for bedside prediction of sepsis.
Using 586 derivation samples and validation across 3,178 independent patients, a six-gene expression signature (Sepset) predicted 24-hour clinical deterioration in suspected sepsis. An RT-PCR assay and an automated centrifugal microfluidic instrument achieved 94% and 92% sensitivity, respectively, with 89% specificity on the instrument.
Impact: This work bridges transcriptomic risk stratification with a deployable bedside device, addressing diagnostic delays that drive sepsis mortality.
Clinical Implications: If prospectively implemented, the Sepset platform could enable early escalation/de-escalation decisions within the first 24 hours, improving triage, ICU utilization, and timely antimicrobial and organ support.
Key Findings
- Defined a six-gene Sepset signature predicting 24-hour deterioration in suspected sepsis
- Validated performance in 3,178 independent patients from external cohorts
- RT-PCR Sepset test showed 94% sensitivity for worsening SOFA within 24 hours
- Automated centrifugal microfluidic device achieved 92% sensitivity and 89% specificity at bedside
Methodological Strengths
- Prospective derivation with cross-validation and large-scale external validation
- Translation to a rapid RT-PCR assay and automated microfluidic platform
Limitations
- Impact on patient-centered outcomes not yet tested in randomized implementation trials
- Potential site-specific biases in derivation cohort despite external validation
Future Directions: Conduct pragmatic implementation trials to assess time-to-antibiotics, ICU admission decisions, and mortality; evaluate performance across diverse health systems and pathogens; pursue regulatory approval and cost-effectiveness analyses.
Sepsis is a life-threatening organ dysfunction due to a dysfunctional response to infection. Delays in diagnosis have substantial impact on survival. Herein, blood samples from 586 in-house patients with suspected sepsis are used in conjunction with machine learning and cross-validation to define a six-gene expression signature of immune cell reprogramming, termed Sepset, to predict clinical deterioration within the first 24 h (h) of clinical presentation. Prediction accuracy (~90% in early inte
2. Endothelial TREM-1 mediates sepsis-induced blood‒brain barrier disruption and cognitive impairment via the PI3K/Akt pathway.
Using iPSC-derived BBB and CLP sepsis models, the study shows endothelial TREM-1 upregulation drives BBB disruption and cognitive impairment via PI3K/Akt signaling. Endothelial-specific TREM-1 knockout preserved BBB integrity and cognition, and PI3K inhibition abrogated the protective effects of TREM-1 inhibition.
Impact: Identifies a tractable endothelial target and pathway for sepsis-associated encephalopathy, linking patient-derived stimuli to in vivo cognitive outcomes.
Clinical Implications: Endothelial TREM-1 and PI3K/Akt signaling represent candidate targets to preserve BBB integrity and mitigate cognitive sequelae in sepsis; biomarkers of endothelial activation could enable stratification for neuroprotective interventions.
Key Findings
- Sepsis patient serum disrupts structure and function of iPSC-derived BBB
- Endothelial TREM-1 expression is upregulated in BBB models and CLP mice
- Endothelial-specific TREM-1 knockout attenuates BBB dysfunction and cognitive impairment
- PI3K/Akt signaling mediates TREM-1 effects; PI3K inhibition abolishes protection from TREM-1 inhibition
Methodological Strengths
- Multipronged preclinical approach combining human iPSC-derived BBB and in vivo CLP models
- Cell type-specific genetic manipulation (endothelial TREM-1 knockout) with pathway interrogation
Limitations
- Preclinical models; lack of human interventional data
- Quantitative sample sizes and reproducibility across laboratories not detailed
Future Directions: Develop and test endothelial TREM-1 inhibitors or modulators in large-animal models and early-phase trials; evaluate circulating markers of endothelial TREM-1 activation for patient stratification in SAE.
The blood‒brain barrier (BBB) is a critical selective interface between the central nervous system (CNS) and the blood circulation. BBB dysfunction plays an important role in the neurological damage caused by sepsis. However, the mechanisms underlying the disruption of the BBB during sepsis remain unclear. We established a human induced pluripotent stem cell (iPSC)-derived BBB model and reported that treating with sepsis patient serum leads to structural and functional disruption of the BBB. In a cec
3. [Ability of midregional proadrenomedullin (MR-proADM) to predict poor clinical outcome and stratify prognosis in adult patients seen for suspected infection in the Emergency Department].
In 214 ED patients with suspected infection, MR-proADM achieved an AUC of 0.920 for predicting septic shock/ICU admission and 30-day mortality, outperforming PCT, lactate, CRP, leukocytes, and NEWS-2. A cutoff >2.105 nmol/L yielded specificity 98% and NPV 97%; combining MR-proADM with NEWS-2 improved prediction metrics.
Impact: Provides pragmatic ED risk stratification evidence showing MR-proADM can surpass widely used biomarkers and scores, supporting early disposition decisions.
Clinical Implications: Incorporating MR-proADM into ED protocols could improve identification of high-risk patients for early ICU admission and closer monitoring while safely de-escalating care in low-risk individuals.
Key Findings
- MR-proADM predicted poor outcomes and 30-day mortality with AUC 0.920
- Cutoff >2.105 nmol/L yielded specificity 98% and NPV 97%
- Outperformed PCT, lactate, CRP, leukocyte count, qSOFA, SIRS, and NEWS-2
- Combining MR-proADM with NEWS-2 further improved prediction metrics
Methodological Strengths
- Prospective observational design with 30-day follow-up
- Direct head-to-head comparison with multiple biomarkers and clinical scores
Limitations
- Single-center cohort with modest sample size limits generalizability
- Sensitivity at the chosen cutoff (68%) may miss some high-risk patients
Future Directions: Multicenter validation, assessment of clinical impact on triage decisions and outcomes, and cost-effectiveness analyses for routine ED implementation.
OBJECTIVES: To analyze and compare the accuracy of midregional proadrenomedullin (MR-proADM) to predict poor clinical outcome (understood as progression to septic shock or admission to the Critical Care Unit -CCU-) and 30-day mortality in adult patients seen for suspected infection in the Emergency Department (ED). We also compared their performance with other biomarkers (C-reactive protein -CRP-, procalcitonin -PCT-, lactate and leukocyte count) and clinical scales widely used in routine practi